<DOC>
	<DOCNO>NCT00616720</DOCNO>
	<brief_summary>RATIONALE : Biological therapy , interferon-gamma aldesleukin , may stimulate immune system different way stop cancer cell grow . Vaccines make person 's white blood cell may help body build effective immune response kill cancer cell . Giving biological therapy together vaccine therapy may kill cancer cell . PURPOSE : This randomized phase II trial study well give aldesleukin interferon gamma together vaccine therapy work treat patient multiple myeloma .</brief_summary>
	<brief_title>Interferon-gamma Aldesleukin Vaccine Therapy Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess clinical benefit patient plateau phase multiple myeloma treat interferon-gamma v aldesleukin combination idiotype-pulsed autologous dendritic cell vaccine APC8020 . - To describe response rate patient plateau phase status post-chemotherapy status post-peripheral blood cell transplantation treat regimen . Secondary - To obtain data regard ability approach produce anti-idiotypic immunologic response . - To obtain information effect interferon-gamma aldesleukin number , function , activation state immune effector-cells include T-cells B-cells . - To perform detailed analysis lymphocyte phenotype T-cell repertoires idiotype-pulsed autologous dendritic cell vaccine APC8020 . OUTLINE : Patients stratify accord gender ( male v female ) prior treatment ( post-chemotherapy v post-peripheral blood stem cell transplantation ) . Patients randomize 1 2 arm . In arm , patient undergo apheresis collection peripheral blood mononuclear cell generation dendritic cell ( DC ) day 0 , 14 , 28 . APC8020 generate load DC immunoglobulin idiotype prepare patient 's serum . - Arm I : Patients receive interferon-gamma subcutaneously ( SC ) daily day 1-5 , 15-20 , 29-34 idiotype-pulsed autologous dendritic cell vaccine APC8020 IV 30-minutes day 2 , 16 , 30 . - Arm II : Patients receive aldesleukin SC daily day 1-5 , 15-20 , 29-34 idiotype-pulsed autologous dendritic cell vaccine APC8020 arm I . In arm , treatment continue absence disease progression . Peripheral blood sample collect baseline day 5 course 1 4 cytokine immunomodulatory study , include immunophenotyping lymphocyte phenotypic marker ( CD69 , CD40L , CD25 , CD30 , CD71 , CDW137 , CD134 , HLADR ) flow cytometry immunofluorescence ; T-cell spectratyping PCR RT-PCR ; T-cell proliferation idiotype protein ; CTL T-helper response flow cytometry . After completion study treatment , patient follow every 3 month 2 year every 6 month thereafter .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Immunoglobulin Idiotypes</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma Plateau phase multiple myeloma ( status post chemotherapy status postperipheral blood cell transplantation ) , meet follow criterion : Serum urine monoclonal ( M ) protein value must stable ( &lt; 20 % variation ) must disappear Serum M protein &lt; 1 g/dL , 1 following : Quantifiable serum M protein Adequate serum sample store Transfusion Medicine IRB protocol # 69898 Urine M protein &lt; 200 mg/24 hour electrophoresis 2 separate occasion period ≥ 4 week Serum M protein spike ≤ 2.0 g/dL No progressive disease prior autologous stem cell transplantation chemotherapy No nonsecretory light chain myeloma PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 6 month WBC ≥ 1,500/μL Platelet count ≥ 50,000/μL Total bilirubin ≤ 5 time upper limit normal Creatinine ≤ 5.0 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Must adequate venous access apheresis No uncontrolled cardiac disease No uncontrolled infection No illness condition , opinion investigator , may affect safety treatment evaluation study 's endpoint PRIOR CONCURRENT THERAPY : Recovered prior therapy More 4 week since prior standarddose chemotherapy , radiotherapy , immunotherapy More 3 month since prior highdose chemotherapy stem cell transplantation No concurrent corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
</DOC>